Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension

Authors

Michael Nicolle
Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
Masahisa Katsuno (ORCID: https://orcid.org/0000-0001-9453-9311)
Tuan H. Vu (ORCID: https://orcid.org/0000-0001-6839-9765)
Andreas Meisel (ORCID: https://orcid.org/0000-0001-7233-5342)
Djillali Annane (ORCID: https://orcid.org/0000-0001-6805-8944)
Rasha Aguzzi (ORCID: https://orcid.org/0000-0002-8587-7105)
Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
Glen Frick

Institutions

University of North Carolina at Chapel Hill (US)
University Health Network (CA)
University of Toronto (CA)
Université de Versailles Saint-Quentin-en-Yvelines (FR)
University of South Florida (US)
London Health Sciences Centre (CA)
Alexion Pharmaceuticals (United States) (US)
Hôpital Raymond-Poincaré (FR)
AstraZeneca (United States) (US)
Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
Nagoya University (JP)
Charité - Universitätsmedizin Berlin (DE)

Publication Details

Journal: European Journal of Neurology
Published: 2025-04-01
DOI: https://doi.org/10.1111/ene.70158
Citations: 12
Primary Topic: Myasthenia Gravis and Thymoma
Type: article
Field-Weighted Citation Impact: 16.67

Funders

AstraZeneca
Alexion Pharmaceuticals

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension

Michael Nicolle, Renato Mantegazza, James F. Howard, Masahisa Katsuno et al.

Apr 1, 2025

12 citations

European Journal of Neurology

Myasthenia Gravis and Thymoma

16.67

article

Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension

Michael Nicolle, Renato Mantegazza, James F. Howard, Masahisa Katsuno, Tuan H. Vu, Andreas Meisel, Djillali Annane, Rasha Aguzzi, Vera Bril, Glen Frick

April 1, 2025article en

12 citations

Abstract

No abstract available for this paper.

European Journal of NeurologyVol. 32(4)

University of North Carolina at Chapel Hill (US), University Health Network (CA), University of Toronto (CA), Université de Versailles Saint-Quentin-en-Yvelines (FR), University of South Florida (US), London Health Sciences Centre (CA), Alexion Pharmaceuticals (United States) (US), Hôpital Raymond-Poincaré (FR), AstraZeneca (United States) (US), Fondazione IRCCS Istituto Neurologico Carlo Besta (IT), Nagoya University (JP), Charité - Universitätsmedizin Berlin (DE)

AstraZeneca, Alexion Pharmaceuticals

Openalex Percentile: Top 1%

Myasthenia Gravis and Thymoma

16.67

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.